PTEN: Multiple functions in human malignant tumors

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Milella, Michele ^a   Falcone, Italia ^a   Conciatori, Fabiana ^a   Incani, Ursula Cesta ^a   Del Curatolo, Anais ^a   Inzerilli, Nicola ^a   Nuzzo, Carmen M A ^a   Vaccaro, Vanja ^a   Vari, Sabrina ^a   Cognetti, Francesco ^a   Ciuffreda, Ludovica ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer; PHTS; PI3K; PTEN; Subcellular localization

Indexed keywords

FOCAL ADHESION KINASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE ACETYLTRANSFERASE PCAF; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NOTCH1 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN KINASE FYN; PROTEIN P53; PROTEIN VARIANT; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN B; TEMSIROLIMUS; THROMBOSPONDIN 1; THYMOSIN BETA4; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR SNAIL; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CARCINOGENESIS; CELL FUNCTION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; COLORECTAL CANCER; COWDEN SYNDROME; EPIGENETICS; GENE MUTATION; GENE SILENCING; HUMAN; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE GENE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84923599043     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00024     Document Type: Review

References (198)

1. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 275(5308):1943-7. doi: 10.1126/science.275.5308.1943.
2. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res (1997) 57(11):2124-9.
3. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15(4):356-62. doi:10.1038/ng0497-356.
4. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 99(3):323-34. doi:10.1016/S0092-8674(00)81663-3.
5. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A (2012) 109(10):3921-6. doi:10.1073/pnas.1117135109.
6. Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci (2008) 121(Pt 3):249-53. doi:10.1242/jcs.022459.
7. Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science (2013) 341(6144):399-402. doi:10.1126/science.1234907.
8. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307(5712):1098-101. doi:10.1126/science.1106148.
9. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol (1997) 7(10):776-89. doi:10.1016/S0960-9822(06)00336-8.
10. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 22(14):2954-63. doi:10.1200/JCO.2004.02.141.
11. Ciuffreda L, Falcone I, Incani UC, Del Curatolo A, Conciatori F, Matteoni S, et al. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul (2014) 56:66-80. doi:10.1016/j.jbior.2014.07.002.
12. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 7(8):606-19. doi:10.1038/nrg1879.
13. Blind RD. Disentangling biological signaling networks by dynamic coupling of signaling lipids to modifying enzymes. Adv Biol Regul (2014) 54:25-38. doi:10.1016/j.jbior.2013.09.015.
14. Laurent PA, Severin S, Gratacap MP, Payrastre B. Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. Adv Biol Regul (2014) 54:162-74. doi:10.1016/j.jbior.2013.09.006.
15. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 273(22):13375-8. doi:10.1074/jbc.273.22.13375.
16. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 95(23):13513-8. doi:10.1073/pnas.95.23.13513.
17. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 13(5):283-96. doi:10.1038/nrm3330.
18. Hlobilkova A, Guldberg P, Thullberg M, Zeuthen J, Lukas J, Bartek J. Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp Cell Res (2000) 256(2):571-7. doi:10.1006/excr.2000.4867.
19. Leslie NR, Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci (2011) 32(3):131-40. doi:10.1016/j.tips.2010.12.005.
20. Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. PTEN function: the long and the short of it. Trends Biochem Sci (2014) 39(4):183-90. doi:10.1016/j.tibs.2014.02.006.
21. De Melo J, He L, Tang D. The protein-protein interaction-mediated inactivation of PTEN. Curr Mol Med (2014) 14(1):22-33. doi:10.2174/1566524013666131118100542.
22. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 128(1):157-70. doi:10.1016/j.cell.2006.11.042.
23. Sun Z, Huang C, He J, Lamb KL, Kang X, Gu T, et al. PTEN C-terminal deletion causes genomic instability and tumor development. Cell Rep (2014) 6(5):844-54. doi:10.1016/j.celrep.2014.01.030.
24. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 144(2):187-99. doi:10.1016/j.cell.2010.12.020.
25. Chen ZH, Zhu M, Yang J, Liang H, He J, He S, et al. PTEN interacts with histone H1 and controls chromatin condensation. Cell Rep (2014) 8(6):2003-14. doi:10.1016/j.celrep.2014.08.008.
26. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 11(6):555-69. doi:10.1016/j.ccr.2007.04.021.
27. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci U S A (2005) 102(8):2703-6. doi:10.1073/pnas.0409370102.
28. Mounir Z, Krishnamoorthy JL, Robertson GP, Scheuner D, Kaufman RJ, Georgescu MM, et al. Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. Sci Signal (2009) 2(102):ra85. doi:10.1126/scisignal.2000389.
29. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 17(4):461-9. doi:10.1038/nm.2309.
30. Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 149(1):49-62. doi:10.1016/j.cell.2012.02.030.
31. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. Subtle variations in PTEN dose determine cancer susceptibility. Nat Genet (2010) 42(5):454-8. doi:10.1038/ng.556.
32. Alimonti A. PTEN breast cancer susceptibility: a matter of dose. Ecancermedicalscience (2010) 4:192. doi:10.3332/ecancer.2010.192.
33. Tamguney T, Stokoe D. New insights into PTEN. J Cell Sci (2007) 120(Pt 23):4071-9. doi:10.1242/jcs.015230.
34. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 11(4):289-301. doi:10.1038/nrc3037.
35. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res (2012) 18(2):400-7. doi:10.1158/1078-0432.CCR-11-2283.
36. Zhang HY, Liang F, Jia ZL, Song ST, Jiang ZF. PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett (2013) 6(1):161-8. doi:10.3892/ol.2013.1331.
37. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 6(2):117-27. doi:10.1016/j.ccr.2004.06.022.
38. Pandolfi PP. Breast cancer - loss of PTEN predicts resistance to treatment. N Engl J Med (2004) 351(22):2337-8. doi:10.1056/NEJMcibr043143.
39. 3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 12(4):395-402. doi:10.1016/j.ccr.2007.08.030.
40. Kouniavsky G, Zeiger MA. Thyroid tumorigenesis and molecular markers in thyroid cancer. Curr Opin Oncol (2010) 22(1):23-9. doi:10.1097/CCO.0b013e328333846f.
41. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 499(7456):43-9. doi:10.1038/nature12222.
42. Durinck S, Stawiski EW, Pavia-Jimenez A, Modrusan Z, Kapur P, Jaiswal BS, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet (2015) 47(1):13-21. doi:10.1038/ng.3146.
43. Muriel Lopez C, Esteban E, Astudillo A, Pardo P, Berros JP, Izquierdo M, et al. Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs (2012) 30(6):2443-9. doi:10.1007/s10637-012-9836-4.
44. Dellas A, Jundt G, Sartorius G, Schneider M, Moch H. Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas. Clin Cancer Res (2009) 15(7):2456-62. doi:10.1158/1078-0432.CCR-08-1732.
45. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology (2013) 62(1):111-23. doi:10.1111/his.12053.
46. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 161(2):439-47. doi:10.1016/S0002-9440(10)64200-9.
47. Frattini M, Signoroni S, Pilotti S, Bertario L, Benvenuti S, Zanon C, et al. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 65(23):11227. doi:10.1158/0008-5472.CAN-05-2780.
48. Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, et al. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J Cancer Res Clin Oncol (2014) 140(5):737-48. doi:10.1007/s00432-014-1626-2.
49. Molinari F, Frattini M. Functions and regulation of the PTEN gene in colorectal cancer. Front Oncol (2013) 3:326. doi:10.3389/fonc.2013.00326.
50. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res (2006) 66(13):6546-52. doi:10.1158/0008-5472.CAN-06-0384.
51. Wang Y, Digiovanna JJ, Stern JB, Hornyak TJ, Raffeld M, Khan SG, et al. Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc Natl Acad Sci U S A (2009) 106(15):6279-84. doi:10.1073/pnas.0812401106.
52. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr., et al. Braf(V600E) cooperates with PTEN loss to induce metastatic melanoma. Nat Genet (2009) 41(5):544-52. doi:10.1038/ng.356.
53. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 19(17):4868-78. doi:10.1158/1078-0432.CCR-13-0827.
54. Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther (2008) 7(9):1321-5. doi:10.4161/cbt.7.9.6954.
55. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene (2008) 27(41):5416-30. doi:10.1038/onc.2008.239.
56. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 487(7406):239-43. doi:10.1038/nature11125.
57. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature (2011) 470(7333):214-20. doi:10.1038/nature09744.
58. Roychowdhury S, Chinnaiyan AM. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol (2013) 31(15):1866-73. doi:10.1200/JCO.2012.45.3662.
59. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4:127-50. doi:10.1146/annurev.pathol.4.110807.092311.
60. Gronbaek K, Zeuthen J, Guldberg P, Ralfkiaer E, Hou-Jensen K. Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 91(11):4388-90.
61. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood (1998) 92(9):3410-5.
62. Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood (2000) 95(9):2937-42.
63. Cheung AM, Mak TW. PTEN in the haematopoietic system and its therapeutic indications. Trends Mol Med (2006) 12(11):503-5. doi:10.1016/j.molmed.2006.09.002.
64. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res (2006) 30(3):262-5. doi:10.1016/j.leukres.2005.07.008.
65. Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW, et al. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol (2003) 122(3):454-6. doi:10.1046/j.1365-2141.2003.04452.x.
66. Liu TC, Lin PM, Chang JG, Lee JP, Chen TP, Lin SF. Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol (2000) 63(4):170-5. doi:10.1002/(SICI)1096-8652(200004)63:4<170::AID-AJH2>3.0.CO;2-0.
67. Panuzzo C, Crivellaro S, Carra G, Guerrasio A, Saglio G, Morotti A. BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia. PLoS One (2014) 9(10):e110682. doi:10.1371/journal.pone.0110682.
68. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 13(10):1203-10. doi:10.1038/nm1636.
69. Martelli AM, Lonetti A, Buontempo F, Ricci F, Tazzari PL, Evangelisti C, et al. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. Adv Biol Regul (2014) 56:6-21. doi:10.1016/j.jbior.2014.04.004.
70. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell (2013) 24(6):766-76. doi:10.1016/j.ccr.2013.10.022.
71. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 8(5):1178-84.
72. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol (2013) 24(9):2371-6. doi:10.1093/annonc/mdt205.
73. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene (1998) 17(4):475-9. doi:10.1038/sj.onc.1201956.
74. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol (2005) 36(7):768-76. doi:10.1016/j.humpath.2005.05.006.
75. Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer (2010) 69(3):279-83. doi:10.1016/j.lungcan.2009.11.012.
76. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 104(18):7564-9. doi:10.1073/pnas.0702507104.
77. Cordes I, Kluth M, Zygis D, Rink M, Chun F, Eichelberg C, et al. PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology (2013) 63(5):670-7. doi:10.1111/his.12209.
78. Hu TH, Wang CC, Huang CC, Chen CL, Hung CH, Chen CH, et al. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol Rep (2007) 18(6):1417-26. doi:10.3892/or.18.6.1417.
79. Zhong Y, Yan J, Deng M, Hu K, Yao Z, Zou Y, et al. Impaired phosphate and tension homologue deleted on chromosome 10 expression and its prognostic role in radical surgery for hepatocellular carcinoma with family aggregation resulting from hepatitis B and liver cirrhosis. Exp Biol Med (2013) 238(8):866-73. doi:10.1177/1535370213494654.
80. Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, Leo C, et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 101(24):9067-72. doi:10.1073/pnas.0402932101.
81. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 157(4):1097-103. doi:10.1016/S0002-9440(10)64624-X.
82. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov (2011) 1(2):158-69. doi:10.1158/2159-8290.CD-11-0031.
83. van Nederveen FH, Perren A, Dannenberg H, Petri BJ, Dinjens WN, Komminoth P, et al. PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas. J Pathol (2006) 209(2):274-80. doi:10.1002/path.1968.
84. Ortega-Molina A, Efeyan A, Lopez-Guadamillas E, Munoz-Martin M, Gomez-Lopez G, Canamero M, et al. PTEN positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab (2012) 15(3):382-94. doi:10.1016/j.cmet.2012.02.001.
85. Pal A, Barber TM, Van de Bunt M, Rudge SA, Zhang Q, Lachlan KL, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med (2012) 367(11):1002-11. doi:10.1056/NEJMoa1113966.
86. Vellai T, McCulloch D, Gems D, Kovacs AL. Effects of sex and insulin/insulin-like growth factor-1 signaling on performance in an associative learning paradigm in Caenorhabditis elegans. Genetics (2006) 174(1):309-16. doi:10.1534/genetics.106.061499.
87. Wong JT, Kim PT, Peacock JW, Yau TY, Mui AL, Chung SW, et al. PTEN (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia (2007) 50(2):395-403. doi:10.1007/s00125-006-0531-x.
88. Nakashima N, Sharma PM, Imamura T, Bookstein R, Olefsky JM. The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes. J Biol Chem (2000) 275(17):12889-95. doi:10.1074/jbc.275.17.12889.
89. Mosser VA, Li Y, Quon MJ. PTEN does not modulate GLUT4 translocation in rat adipose cells under physiological conditions. Biochem Biophys Res Commun (2001) 288(4):1011-7. doi:10.1006/bbrc.2001.5876.
90. Morani F, Phadngam S, Follo C, Titone R, Aimaretti G, Galetto A, et al. PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. J Mol Endocrinol (2014) 53(2):247-58. doi:10.1530/JME-14-0118.
91. Funamoto S, Milan K, Meili R, Firtel RA. Role of phosphatidylinositol 3' kinase and a downstream pleckstrin homology domain-containing protein in controlling chemotaxis in dictyostelium. J Cell Biol (2001) 153(4):795-810. doi:10.1083/jcb.153.4.795.
92. Huang X, Czerwinski E, Mellgren RL. Purification and properties of the Dictyostelium calpain-like protein, Cpl. Biochemistry (2003) 42(6):1789-95. doi:10.1021/bi026461+.
93. Iijima M, Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell (2002) 109(5):599-610. doi:10.1016/S0092-8674(02)00745-6.
94. Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene (2008) 27(41):5464-76. doi:10.1038/onc.2008.243.
95. Servant G, Weiner OD, Herzmark P, Balla T, Sedat JW, Bourne HR. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science (2000) 287(5455):1037-40. doi:10.1126/science.287.5455.1037.
96. Leslie NR, Downes CP. PTEN: the down side of PI 3-kinase signalling. Cell Signal (2002) 14(4):285-95. doi:10.1016/S0898-6568(01)00234-0.
97. Leslie NR. PTEN: an intercellular peacekeeper? Sci Signal (2012) 5(250):e50. doi:10.1126/scisignal.2003685.
98. Leslie NR, Yang X, Downes CP, Weijer CJ. PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol (2007) 17(2):115-25. doi:10.1016/j.cub.2006.12.026.
99. Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science (2004) 303(5661):1179-81. doi:10.1126/science.1092089.
100. Park MJ, Kim MS, Park IC, Kang HS, Yoo H, Park SH, et al. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res (2002) 62(21):6318-22.
101. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res (2008) 68(6):1862-71. doi:10.1158/0008-5472.CAN-07-1182.
102. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A (2001) 98(8):4622-7. doi:10.1073/pnas.081063798.
103. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev (2000) 14(4):391-6. doi:10.1101/gad.14.4.391.
104. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res (2006) 66(11):5549-54. doi:10.1158/0008-5472.CAN-05-2825.
105. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 11(8):720-31.
106. Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, et al. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl) (2012) 90(6):667-79. doi:10.1007/s00109-011-0844-1.
107. Baker SJ. PTEN enters the nuclear age. Cell (2007) 128(1):25-8. doi:10.1016/j.cell.2006.12.023.
108. Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A, et al. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci (2006) 119(Pt 24):5160-8. doi:10.1242/jcs.000133.
109. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 156(5):1693-700. doi:10.1016/S0002-9440(10)65040-7.
110. Lachyankar MB, Sultana N, Schonhoff CM, Mitra P, Poluha W, Lambert S, et al. A role for nuclear PTEN in neuronal differentiation. J Neurosci (2000) 20(4):1404-13.
111. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem (2001) 276(2):993-8. doi:10.1074/jbc.M009134200.
112. Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res (2003) 63(2):282-6.
113. Chung JH, Ginn-Pease ME, Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res (2005) 65(10):4108-16. doi:10.1158/0008-5472.CAN-05-0124.
114. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 128(1):141-56. doi:10.1016/j.cell.2006.11.040.
115. Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science (2013) 341(6144):395-9. doi:10.1126/science.1236188.
116. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 3(2):117-30. doi:10.1016/S1535-6108(03)00021-7.
117. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A (2008) 105(7):2622-7. doi:10.1073/pnas.0706790105.
118. Putz U, Howitt J, Doan A, Goh CP, Low LH, Silke J, et al. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci Signal (2012) 5(243):ra70. doi:10.1126/scisignal.2003084.
119. Malaney P, Uversky VN, Dave V. The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy. Mol Biosyst (2013) 9(11):2877-88. doi:10.1039/c3mb70267g.
120. Liang H, He S, Yang J, Jia X, Wang P, Chen X, et al. PTENalpha, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism. Cell Metab (2014) 19(5):836-48. doi:10.1016/j.cmet.2014.03.023.
121. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell (2008) 133(3):403-14. doi:10.1016/j.cell.2008.04.013.
122. Stambolic V, Woodgett JR. Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol (2006) 16(9):461-6. doi:10.1016/j.tcb.2006.07.001.
123. Moorehead RA, Hojilla CV, De Belle I, Wood GA, Fata JE, Adamson ED, et al. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem (2003) 278(50):50422-7. doi:10.1074/jbc.M306894200.
124. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol (2001) 3(12):1124-8. doi:10.1038/ncb1201-1124.
125. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol (2001) 11(10):764-8. doi:10.1016/S0960-9822(01)00225-1.
126. Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B, et al. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol (2008) 28(5):1528-40. doi:10.1128/MCB.02061-07.
127. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, et al. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 11(5):447-60. doi:10.1016/j.ccr.2007.03.009.
128. Whelan JT, Forbes SL, Bertrand FE. CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle (2007) 6(1):80-4. doi:10.4161/cc.6.1.3648.
129. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 395(6698):125-6. doi:10.1038/25870.
130. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT, et al. c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ (2007) 14(2):218-29. doi:10.1038/sj.cdd.4401946.
131. Vasudevan KM, Burikhanov R, Goswami A, Rangnekar VM. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res (2007) 67(21):10343-50. doi:10.1158/0008-5472.CAN-07-1827.
132. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 133(2):647-58. doi:10.1053/j.gastro.2007.05.022.
133. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta (2010) 411(11-12):846-52. doi:10.1016/j.cca.2010.02.074.
134. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of the miR-106b ~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 3(117):ra29. doi:10.1126/scisignal.2000594.
135. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev (2009) 23(24):2806-11. doi:10.1101/gad.1872909.
136. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer (2004) 112(3):407-10. doi:10.1002/ijc.20447.
137. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer (2001) 91(1):22-6. doi:10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S.
138. Lu J, Jeong HW, Kong N, Yang Y, Carroll J, Luo HR, et al. Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex. PLoS One (2009) 4(5):e5577. doi:10.1371/journal.pone.0005577.
139. Pan L, Lu J, Wang X, Han L, Zhang Y, Han S, et al. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer (2007) 109(8):1676-88. doi:10.1002/cncr.22585.
140. Vazquez S, Aquilina JA, Jamie JF, Sheil MM, Truscott RJ. Novel protein modification by kynurenine in human lenses. J Biol Chem (2002) 277(7):4867-73. doi:10.1074/jbc.M107529200.
141. Miller SJ, Lou DY, Seldin DC, Lane WS, Neel BG. Direct identification of PTEN phosphorylation sites. FEBS Lett (2002) 528(1-3):145-53. doi:10.1016/S0014-5793(02)03274-X.
142. Mehenni H, Lin-Marq N, Buchet-Poyau K, Reymond A, Collart MA, Picard D, et al. LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum Mol Genet (2005) 14(15):2209-19. doi:10.1093/hmg/ddi225.
143. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem (2005) 280(42):35195-202. doi:10.1074/jbc.M503045200.
144. Correia NC, Girio A, Antunes I, Martins LR, Barata JT. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer (2014) 50(1):216-25. doi:10.1016/j.ejca.2013.08.017.
145. Fragoso R, Barata JT. Kinases, tails and more: regulation of PTEN function by phosphorylation. Methods (2014). doi:10.1016/j.ymeth.2014.10.015.
146. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 128(1):129-39. doi:10.1016/j.cell.2006.11.039.
147. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol (2010) 177(5):2622-34. doi:10.2353/ajpath.2010.091075.
148. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. J Biol Chem (2006) 281(36):26562-8. doi:10.1074/jbc.M605391200.
149. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem (2002) 277(23):20336-42. doi:10.1074/jbc.M111899200.
150. Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 97(8):4233-8. doi:10.1073/pnas.97.8.4233.
151. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell (2005) 7(3):263-73. doi:10.1016/j.ccr.2005.02.010.
152. Kim YC, Kitaura H, Taira T, Iguchi-Ariga SM, Ariga H. Oxidation of DJ-1-dependent cell transformation through direct binding of DJ-1 to PTEN. Int J Oncol (2009) 35(6):1331-41. doi:10.3892/ijo_00000451.
153. Terrien E, Chaffotte A, Lafage M, Khan Z, Prehaud C, Cordier F, et al. Interference with the PTEN-MAST2 interaction by a viral protein leads to cellular relocalization of PTEN. Sci Signal (2012) 5(237):ra58. doi:10.1126/scisignal.2002941.
154. Zmajkovicova K, Jesenberger V, Catalanotti F, Baumgartner C, Reyes G, Baccarini M. MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance. Mol Cell (2013) 50(1):43-55. doi:10.1016/j.molcel.2013.01.037.
155. Eng C. PTEN: one gene, many syndromes. Hum Mutat (2003) 22(3):183-98. doi:10.1002/humu.10257.
156. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 16(1):64-7. doi:10.1038/ng0597-64.
157. Mester JL, Moore RA, Eng C. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing? Oncologist (2013) 18(10):1083-90. doi:10.1634/theoncologist.2013-0174.
158. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 7(3):507-15. doi:10.1093/hmg/7.3.507.
159. Herman GE, Butter E, Enrile B, Pastore M, Prior TW, Sommer A. Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. Am J Med Genet A (2007) 143A(6):589-93. doi:10.1002/ajmg.a.31619.
160. Garcia-Junco-Clemente P, Golshani P. PTEN: a master regulator of neuronal structure, function, and plasticity. Commun Integr Biol (2014) 7(1):e28358. doi:10.4161/cib.28358.
161. Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat (2000) 16(2):109-22. doi:10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0.
162. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 96(8):4240-5. doi:10.1073/pnas.96.8.4240.
163. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. PTEN is essential for embryonic development and tumour suppression. Nat Genet (1998) 19(4):348-55. doi:10.1038/1235.
164. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al. Mutation of PTEN/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 96(4):1563-8. doi:10.1073/pnas.96.4.1563.
165. Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little? Cancer Res (2011) 71(3):629-33. doi:10.1158/0008-5472.CAN-10-2488.
166. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, et al. Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A (2001) 98(20):11563-8. doi:10.1073/pnas.201167798.
167. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. PTEN dose dictates cancer progression in the prostate. PLoS Biol (2003) 1(3):E59. doi:10.1371/journal.pbio.0000059.
168. Hill R, Wu H. PTEN, stem cells, and cancer stem cells. J Biol Chem (2009) 284(18):11755-9. doi:10.1074/jbc.R800071200.
169. Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, Le Belle J, Zack JA, et al. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2006) 103(1):111-6. doi:10.1073/pnas.0509939103.
170. Inoue-Narita T, Hamada K, Sasaki T, Hatakeyama S, Fujita S, Kawahara K, et al. PTEN deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res (2008) 68(14):5760-8. doi:10.1158/0008-5472.CAN-08-0889.
171. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 441(7092):518-22. doi:10.1038/nature04747.
172. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, et al. PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 441(7092):475-82. doi:10.1038/nature04703.
173. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 104(41):16158-63. doi:10.1073/pnas.0702596104.
174. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, et al. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology (2011) 140(1):297-309. doi:10.1053/j.gastro.2010.10.005.
175. Ricci-Vitiani L, Mollinari C, di Martino S, Biffoni M, Pilozzi E, Pagliuca A, et al. Thymosin beta4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB J (2010) 24(11):4291-301. doi:10.1096/fj.10-159970.
176. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res (2008) 68(15):6145-53. doi:10.1158/0008-5472.CAN-08-1430.
177. 3K-dependent feedback loop in human cancer. J Clin Invest (2008) 118(9):3065-74. doi:10.1172/JCI34739.
178. 3K pathway: of feedbacks and cross-talks. Oncogene (2008) 27(41):5527-41. doi:10.1038/onc.2008.247.
179. Byron SA, Loch DC, Wellens CL, Wortmann A, Wu JY, Wang J, et al. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer (2012) 11:75. doi:10.1186/1476-4598-11-75.
180. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene (2012) 31(4):446-57. doi:10.1038/onc.2011.250.
181. Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN, et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer (2011) 11:123. doi:10.1186/1471-2407-11-123.
182. Chowdhury S, Ongchin M, Wan G, Sharratt E, Brattain MG, Rajput A. Restoration of PTEN activity decreases metastases in an orthotopic model of colon cancer. J Surg Res (2013) 184(2):755-60. doi:10.1016/j.jss.2013.03.035.
183. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell (2000) 100(4):387-90. doi:10.1016/S0092-8674(00)80674-1.
184. Schade B, Rao T, Dourdin N, Lesurf R, Hallett M, Cardiff RD, et al. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem (2009) 284(28):19018-26. doi:10.1074/jbc.M109.018937.
185. Fabi A, Metro G, Di Benedetto A, Nistico C, Vici P, Melucci E, et al. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology (2010) 78(2):141-9. doi:10.1159/000312656.
186. 3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia (2008) 22(4):686-707. doi:10.1038/leu.2008.26.
187. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell (2007) 129(7):1261-74. doi:10.1016/j.cell.2007.06.009.
188. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets (2010) 10(5):484-95. doi:10.2174/156800910791517172.
189. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 10(5):307-18. doi:10.1038/nrm2672.
190. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 328(5982):1172-6. doi:10.1126/science.1187532.
191. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 18(1):39-51. doi:10.1016/j.ccr.2010.05.023.
192. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 1(6-7):315-22. doi:10.1002/emmm.200900041.
193. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res (2010) 70(13):5457-64. doi:10.1158/0008-5472.CAN-09-4295.
194. Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, et al. Polo-like kinase 1 facilitates loss of PTEN tumor suppressor-induced prostate cancer formation. J Biol Chem (2011) 286(41):35795-800. doi:10.1074/jbc.C111.269050.
195. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (1998) 280(5369):1614-7. doi:10.1126/science.280.5369.1614.
196. Gu T, Zhang Z, Wang J, Guo J, Shen WH, Yin Y. CREB is a novel nuclear target of PTEN phosphatase. Cancer Res (2011) 71(8):2821-5. doi:10.1158/0008-5472.CAN-10-3399.
197. 3K) as therapeutic targets in NSCLC. Curr Pharm Des (2014) 20(24):3944-57. doi:10.2174/13816128113196660763.
198. Boosani CS, Agrawal DK. PTEN modulators: a patent review. Expert Opin Ther Pat (2013) 23(5):569-80. doi:10.1517/13543776.2013.768985.